Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Clinical Pharmacology and Therapeutics|August 29, 2014
A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic responseT H T Nguyen, F Mentré, M Levi, et al.
L'Encephale|November 14, 2006
[Therapeutics approach of adult patients with acute and chronic psychotic states: REALITE survey]F R Cousin, J P Chabannes, M J Guedj, et al.
Journal of Viral Hepatitis|June 9, 2012
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirinH Guedj, J Guedj, F Negro, et al.
L'Encephale|August 10, 2013
[Decision of emergency involuntary hospitalization: categorical or dimensional approach?]A Braitman, V Dauriac-Le Masson, F Beghelli, et al.
ESMO Open|December 26, 2021
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapyM Kerioui, S Desmée, F Mercier, et al.
Alimentary Pharmacology & Therapeutics|December 23, 2017
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitorS Fourati, J Guedj, S Chevaliez, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Research Square|February 23, 2021
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical modelsP Maisonnasse, Y Aldon, A Marc, et al.
Pageof 2